{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:38:05Z","timestamp":1792579085263,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The progressive ageing of people living with HIV (PLWH) has increased hepatic and metabolic comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study evaluates the impact of HIV-related, metabolic and behavioural factors on hepatic steatosis and fibrosis development using vibration-controlled transient elastography (VCTE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a single-centre cross-sectional study evaluating an Italian cohort of PLWH at an academic medical centre. Steatosis (via CAP, dB\/m) and fibrosis (kPa) were assessed using VCTE. Lifestyle habits were investigated through a structured questionnaire. Factors associated with severe steatosis (S3) and with fibrosis were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 265 patients were included (median age 53.9\u2005years; 89.4% with HIV-RNA\u200a&amp;lt;\u200a50\u2005copies\/mL; median CD4 count 758\u2005cells\/mm3). Moderate-to-severe steatosis (S2\u2013S3) affected 49% of the cohort (S3: 28.5%). In multivariate analysis, independent predictors of severe (S3) steatosis were longer cumulative integrase inhibitor (InSTI) exposure (aOR 1.19\/year, P\u200a=\u200a0.002), higher BMI (aOR 1.45 per kg\/m2, P\u200a&amp;lt;\u200a0.001), daily alcohol consumption (aOR 2.41, P\u200a=\u200a0.031) and higher LDL cholesterol (aOR 1.20 per +10\u2005mg\/dL, P\u200a=\u200a0.003). Regular physical activity was associated with lower CAP. Higher CAP values showed an independent association with increased liver stiffness (mean change +0.07\u2005kPa per +10\u2005db\/m, P\u200a=\u200a0.016), while virological suppression (HIV-RNA\u200a&amp;lt;\u200a50\u2005copies\/mL) was significantly associated with reduced liver stiffness (mean change \u22121.61\u2005kPa, P\u200a=\u200a0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Hepatic steatosis and fibrosis are highly prevalent in PLWH. Cumulative InSTI exposure and metabolic factors may drive severe steatosis, which may accelerate fibrotic damage, whereas effective virological suppression can significantly lower fibrosis risk. Strict metabolic monitoring and lifestyle interventions should be integrated into PLWH long-term care protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag351","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:39:08Z","timestamp":1792575548000},"source":"Crossref","is-referenced-by-count":0,"title":["Cumulative exposure to integrase inhibitors and metabolic factors as independent predictors of severe hepatic steatosis in people with HIV"],"prefix":"10.1093","volume":"81","author":[{"given":"Francesca","family":"Panza","sequence":"first","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena , Siena ,","place":["Italy"]},{"name":"Infectious and Tropical Diseases Unit, Siena University Hospital , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Crispo","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena , Siena ,","place":["Italy"]},{"name":"Infectious and Tropical Diseases Unit, Siena University Hospital , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Sambo","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena , Siena ,","place":["Italy"]},{"name":"Infectious and Tropical Diseases Unit, Siena University Hospital , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bailoni","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena , Siena ,","place":["Italy"]},{"name":"Infectious and Tropical Diseases Unit, Siena University Hospital , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Morelli","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena , Siena ,","place":["Italy"]},{"name":"Infectious and Tropical Diseases Unit, Siena University Hospital , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Giuliano","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena , Siena ,","place":["Italy"]},{"name":"Infectious and Tropical Diseases Unit, Siena University Hospital , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Romano","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pippi","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Siena University Hospital , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Trezzi","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Siena University Hospital , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Montagnani","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena , Siena ,","place":["Italy"]},{"name":"Infectious and Tropical Diseases Unit, Siena University Hospital , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9519-8552","authenticated-orcid":false,"given":"Mario","family":"Tumbarello","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena , Siena ,","place":["Italy"]},{"name":"Infectious and Tropical Diseases Unit, Siena University Hospital , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-812X","authenticated-orcid":false,"given":"Massimiliano","family":"Fabbiani","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena , Siena ,","place":["Italy"]},{"name":"Infectious and Tropical Diseases Unit, Siena University Hospital , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"2026102105390065900_dkag351-B1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11904-020-00483-5","article-title":"Obesity and weight gain in persons with HIV","volume":"17","author":"Bailin","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2026102105390065900_dkag351-B2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000539371","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2024","journal-title":"Obes Facts"},{"key":"2026102105390065900_dkag351-B3","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25484","article-title":"Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada","volume":"23","author":"Bourgi","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"2026102105390065900_dkag351-B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/QCO.0000000000000616","article-title":"Weight gain and integrase inhibitors","volume":"33","author":"Eckard","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2026102105390065900_dkag351-B5","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/QAI.0000000000001525","article-title":"Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor\u2013based regimens","volume":"76","author":"Norwood","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026102105390065900_dkag351-B6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/COH.0000000000000680","article-title":"Impact of integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV","volume":"16","author":"Lake","year":"2021","journal-title":"Curr Opin HIV AIDS"},{"key":"2026102105390065900_dkag351-B7","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab542","article-title":"Excess weight gain with integrase inhibitors and tenofovir alafenamide: what is the mechanism and does it matter?","volume":"8","author":"Wood","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026102105390065900_dkag351-B8","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/cid\/ciab444","article-title":"Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials","volume":"73","author":"Erlandson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026102105390065900_dkag351-B9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.15585\/mmwr.mm7022a1","article-title":"Estimated annual number of HIV infections \u2500 United States, 1981\u20132019","volume":"70","author":"Bosh","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026102105390065900_dkag351-B10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026102105390065900_dkag351-B11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/diagnostics12010014","article-title":"Discordant liver fibrosis predictors in virologically suppressed people living with HIV without hepatitis virus infection","volume":"12","author":"Rossetti","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2026102105390065900_dkag351-B12","author":"European AIDS Clinical Society"},{"key":"2026102105390065900_dkag351-B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101116","article-title":"Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)","volume":"40","author":"Bischoff","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2026102105390065900_dkag351-B14","volume-title":"Waist Circumference and waist-hip Ratio: Report of a WHO Expert Consultation","author":"World Health Organization","year":"2008"},{"key":"2026102105390065900_dkag351-B15","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"2026102105390065900_dkag351-B16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2337\/diacare.23.1.57","article-title":"Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity","volume":"23","author":"Bonora","year":"2000","journal-title":"Diabetes Care"},{"key":"2026102105390065900_dkag351-B17","author":"American college of Cardiology"},{"key":"2026102105390065900_dkag351-B18","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026102105390065900_dkag351-B19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/09540121.2018.1545990","article-title":"Beyond viral suppression: the quality of life of people living with HIV in Sweden","volume":"31","author":"Zeluf-Andersson","year":"2019","journal-title":"AIDS Care"},{"key":"2026102105390065900_dkag351-B20","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1097\/QAD.0000000000001504","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection","volume":"31","author":"Maurice","year":"2017","journal-title":"AIDS"},{"key":"2026102105390065900_dkag351-B21","doi-asserted-by":"publisher","first-page":"9158","DOI":"10.1038\/s41598-023-32965-y","article-title":"Metabolic dysfunction-associated fatty liver disease in people living with HIV","volume":"13","author":"Michel","year":"2023","journal-title":"Sci Rep"},{"key":"2026102105390065900_dkag351-B22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11904-022-00600-6","article-title":"Metabolic consequences of antiretroviral therapy","volume":"19","author":"Diggins","year":"2022","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2026102105390065900_dkag351-B23","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12879-023-08530-3","article-title":"The impact of integrase inhibitors on steatosis and fibrosis biomarkers in persons with HIV na\u00efve to antiretroviral therapy","volume":"23","author":"Fernandes","year":"2023","journal-title":"BMC Infect Dis"},{"key":"2026102105390065900_dkag351-B24","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026102105390065900_dkag351-B25","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/QAD.0000000000004462","article-title":"Metabolic dysfunction-associated steatotic liver disease linked to antiretroviral exposure in cohort of people with HIV","volume":"40","author":"Lindhardt","year":"2026","journal-title":"AIDS"},{"key":"2026102105390065900_dkag351-B26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/hiv.13146","article-title":"Efficacy and durability of two- vs. Three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: data from real-life ODOACRE cohort","volume":"22","author":"Fabbiani","year":"2021","journal-title":"HIV Med"},{"key":"2026102105390065900_dkag351-B27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1086\/589294","article-title":"Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors","volume":"47","author":"Guaraldi","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026102105390065900_dkag351-B28","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.3390\/nu15081990","article-title":"Nutritional and lifestyle therapy for NAFLD in people with HIV","volume":"15","author":"Cinque","year":"2023","journal-title":"Nutrients"},{"key":"2026102105390065900_dkag351-B29","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1097\/QAD.0000000000003903","article-title":"The effect of weight gain and metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in people with HIV","volume":"38","author":"Guaraldi","year":"2024","journal-title":"AIDS"},{"key":"2026102105390065900_dkag351-B30","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1111\/hiv.70079","article-title":"Metabolic dysfunction-associated liver disease predicts incident liver fibrosis in people with HIV mono-infection: a cohort study","volume":"26","author":"Fittipaldi","year":"2025","journal-title":"HIV Med"},{"key":"2026102105390065900_dkag351-B31","doi-asserted-by":"publisher","first-page":"e2127","DOI":"10.1097\/MD.0000000000002127","article-title":"Liver fibrosis in HIV patients receiving a modern cART: which factors play a role?","volume":"94","author":"Mohr","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2026102105390065900_dkag351-B32","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv015","article-title":"Incidence and predictors of hepatic steatosis and fibrosis by Serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients","volume":"2","author":"Sebastiani","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2026102105390065900_dkag351-B33","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1097\/QAI.0000000000001936","article-title":"Diagnostic accuracy of noninvasive markers of steatosis, NASH, and liver fibrosis in HIV-monoinfected individuals at risk of nonalcoholic fatty liver disease (NAFLD): results from the ECHAM study","volume":"80","author":"Lemoine","year":"2019","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/11\/dkag351\/72221922\/dkag351.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/11\/dkag351\/72221922\/dkag351.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:39:08Z","timestamp":1792575548000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag351\/8960342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag351","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,10,6]]},"article-number":"dkag351"}}